Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs PubMatic Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.68 (market cap $29.60B), while PubMatic Inc trades at $17.43 (market cap $804.41M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 36.8× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PUBM | |
|---|---|---|
Market Cap | $29.60B | $804.41M |
Sector | Health | Technology |
52-Week High | $491.22 | $17.78 |
52-Week Low | $205.48 | $6.28 |
Enterprise Value | $27.56B | $707.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
PubMatic trades at $17.39, down 2.08% today, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue reached $282.93M in 2025, though net income was negative. Recent Q2 2026 earnings beat expectations with 10.5% revenue growth, and the company appointed a new Chief Revenue Officer to drive AI-advertising growth.
The stock offers upside to the $20.83 consensus price target, supported by analyst buy ratings and operational cash flow strength. Risks include persistent unprofitability, high P/E ratio, and CFO transition. Positive sentiment from recent earnings beats and strategic hires suggests potential for recovery if margin improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
